EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial

Mehrnaz Valadan, Zohre Raisian, Elham Feizabad, Nafiseh Saedi

Fertility, Gynecology and Andrology · 2022

DOI: 10.5812/fga-129216 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Fertility, Gynecology and Andrology, 2022. Verfasst von Mehrnaz Valadan und 3 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical ripening is the process of initiating labor in women with an unripe cervix. Vaginally administered prostaglandin E1 analog (misoprostol) has been promising in cervical ripening and labor induction. However, optimal dosage and dose-dependent adverse effects in this administration route need further clarification.

Objectives

This trial aimed to compare the efficacy and adverse effects of 50 mcg vs. 25 mcg of vaginal misoprostol in low-risk term pregnant women.

Methods

This double-blind, single-center, randomized clinical trial included 200 low-risk term pregnancies undergoing labor induction with a Bishop score of 2 or less. Patients were assigned randomly to receive 25 mcg or 50 mcg of vaginal misoprostol every six hours up to four times until the active phase of labor was reached. The primary outcome included time to vaginal delivery (latent and active phase of labor), and secondary outcomes included the total dosage of prescribed misoprostol, the need for oxytocin for labor augmentation, and the cesarean section rate.

Results

Misoprostol 50 micrograms resulted in a significantly shorter time in the first phase of labor (P-value = 0.002), the second phase of labor (P-value = 0.030), and the third phase of labor (P-value = 0.020). The number of administered misoprostol, the need for additional oxytocin, uterine hyperstimulation, cesarean delivery rate, Apgar score, umbilical artery pH, and neonatal intensive care unit (NICU) administration were statistically similar between the two groups.

Conclusions

This study showed that 50 mcg of vaginal misoprostol (vs. 25 mcg) for cervical ripening could reduce labor phase duration without significantly increasing adverse maternal and neonatal outcomes.

Zitieren

APA

Valadan, M., Raisian, Z., Feizabad, E., & Saedi, N. (2022). Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial. Fertility, Gynecology and Andrology. https://doi.org/10.5812/fga-129216

Vancouver

Valadan M, Raisian Z, Feizabad E, Saedi N. Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial. Fertility, Gynecology and Andrology. 2022. doi:10.5812/fga-129216

BibTeX
@article{Valadan2022,
  author = {Valadan, Mehrnaz and Raisian, Zohre and Feizabad, Elham and Saedi, Nafiseh},
  title = {Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial},
  journal = {Fertility, Gynecology and Andrology},
  year = {2022},
  doi = {10.5812/fga-129216}
}
Kostenlos starten →